Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Open Label, Dose-escalation Study of the Safety and OcUlar Tolerability of a Single Intravitreal Injection of RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration (SUSHI)

Trial Profile

Phase 1/2 Open Label, Dose-escalation Study of the Safety and OcUlar Tolerability of a Single Intravitreal Injection of RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration (SUSHI)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Oct 2018

At a glance

  • Drugs RBM 007 (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions
  • Acronyms SUSHI
  • Sponsors Ribomic
  • Most Recent Events

    • 30 Oct 2018 According to a Ribomic media release, first patient has been enrolled.
    • 20 Sep 2018 Status changed from not yet recruiting to recruiting.
    • 23 Aug 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top